| Amivantamab studied in …STUDIED_INderived40 of 40show fewer |
|---|
| → studied in | NCT05845671Phase 1/Phase 2 · active not recruiting Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations · 40 trials list this drug (34 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07107230Phase 1 · recruiting A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors · 40 trials list this drug (34 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04487080Phase 3 · active not recruiting A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04988295Phase 3 · active not recruiting A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05388669Phase 3 · active not recruiting A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05498428Phase 2 · recruiting A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02609776Phase 1 · active not recruiting Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05379595Phase 1/Phase 2 · recruiting A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer · 40 trials list this drug (34 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05488314Phase 1/Phase 2 · active not recruiting A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05663866Phase 2 · active not recruiting Premedication to Reduce Amivantamab Associated Infusion Related Reactions · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05908734Phase 1/Phase 2 · active not recruiting A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06120140Phase 2 · active not recruiting Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06385080Phase 1/Phase 2 · recruiting A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer · 40 trials list this drug (34 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06662786Phase 3 · recruiting A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer · 40 trials list this drug (34 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06667076Phase 2 · recruiting A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06750094Phase 3 · recruiting A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy · 40 trials list this drug (34 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227025Phase 1/Phase 2 · recruiting A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07276399Phase 3 · recruiting A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer · 40 trials list this drug (34 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07586202Phase 2 · recruiting A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07808359Phase 2 · not yet recruiting Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma · 40 trials list this drug (34 active) | — | — | Penile Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05845450Phase 2 · recruiting Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) · 40 trials list this drug (34 active) | — | — | Colorectal Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06083857Phase 1/Phase 2 · active not recruiting PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05801029Phase 2 · active not recruiting A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06507306Phase 1 · active not recruiting A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies · 40 trials list this drug (34 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04538664Phase 3 · active not recruiting A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05299125Phase 2 · completed Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06632236Phase 1 · active not recruiting 5G-EMERALD: Amivantamab in Malignant Brain Tumours · 40 trials list this drug (34 active) | — | — | Glioblastoma,Diffuse Hemispheric Glioma, H3 G34-Mutant | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06532032Phase 1/Phase 2 · completed A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04077463Phase 1 · active not recruiting A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05074940Phase 2 · active not recruiting Amivantamab in Adenoid Cystic Carcinoma · 40 trials list this drug (34 active) | — | — | Malignant Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06116682Phase 2 · recruiting Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05117931Phase 2 · active not recruiting A Study of Amivantamab in People With Esophagogastric Cancer · 40 trials list this drug (34 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07392658Phase 2 · recruiting Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations. · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05601973Phase 2 · active not recruiting Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04965090Phase 2 · completed A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784791Phase 2 · recruiting Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR) · 40 trials list this drug (34 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04599712approved for marketing Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer · 40 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05653427Phase 2 · terminated A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma · 40 trials list this drug (34 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04945733Phase 2 · terminated A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer · 40 trials list this drug (34 active) | — | — | Esophageal Neoplasm,Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03767075Phase 2 · recruiting A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) · 40 trials list this drug (34 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |